Plain Language Summary on Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to < 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa‐ PROTECT Main Study
Articles > Article · 2026
Authors: Margareth C. Ozelo, Matteo Luciani, Heidi Glosli, Kaan Kavakli, Nasrin Samji, Gregory C. Makris, Claudia Tueckmantel, Monika Maas Enriquez, Luciana C. Oliveira, Shveta Gupta, Mario Guillermo Arbesú, Mauro Davoli, Anthony K. C. Chan, Maria Elisa Mancuso
European Journal of Haematology, International, WoS, 2026, vol 116, pp 471-472
DOI: 10.1111/ejh.70078
Summary
This is a plain language summary describing results from the Alfa-PROTECT study on safety and efficacy of damoctocog alfa pegol in previously treated children aged between 7 and 12 years with severe haemophilia A. Trial Registration: The Alfa-PROTECT trial is registered at ClinicalTrials.gov: NCT05147662.